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Abstract
Although hyperlipidemia is common in COPD, its relationship to comorbidities, risk factors
and lung function in COPD has not been studied in detail. Using the baseline data of the
COSYCONET cohort we addressed this question. Data from 1746 COPD patients (GOLD
stage 1–4; mean age 64.6 y, mean FEV1%pred 57%) were evaluated, focusing on the
comorbidities hyperlipidemia, diabetes and cardiovascular complex (CVC; including arterial
hypertension, cardiac failure, ischemic heart disease). Risk factors comprised age, gender,
BMI, and packyears of smoking. The results of linear and logistic regression analyses were
implemented into a path analysis model describing the multiple relationships between
parameters. Hyperlipidemia (prevalence 42.9%) was associated with lower intrathoracic
gas volume (ITGV) and higher forced expiratory volume in 1 second (FEV1) when adjusting
for its multiple relationships to risk factors and other comorbidities. These findings were
robust in various statistical analyses. The associations between comorbidities and risk fac-
tors were in accordance with previous findings, thereby underlining the validity of our data.
In conclusion, hyperlipidemia was associated with less hyperinflation and airway obstruction
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in patients with COPD. This surprising result might be due to different COPD phenotypes in
these patients or related to effects of medication.
Introduction
Hyperlipidemia is a major risk factor for cardiovascular diseases which are common comor-
bidities in patients with chronic obstructive pulmonary disease (COPD) [1], but there are only
limited studies on its role in COPD itself [2, 3]. Although most comorbidities are associated
with increased mortality, retrospective analyses revealed a decreased incidence of pneumonia
and reduced mortality in COPD patients with hyperlipidemia [4, 5]. Thus the role of hyperlip-
idemia remains unclear and its relationship to other comorbidities, risk factors and pulmonary
function has to be studied in more detail.
In subjects with metabolic syndrome and hyperlipidemia but no obvious lung disease a
restrictive spirometric lung function pattern was observed [6–8], but this has not been verified
e.g. by bodyplethysmography. The relation of hyperlipidemia to lung function in COPD is
unclear but of interest owing to physiological findings. Lipoproteins can influence blood rheol-
ogy, including plasma viscosity, aggregation and deformation of erythrocytes [9, 10], and
in vitro they led to accumulation of erythrocytes in the pulmonary capillary bed [11]. Thus it
has been hypothesized that a higher capillary red cell volume would lead to an increase in the
diffusing capacity for carbon monoxide (TLCO). At least in lung-healthy subjects, however,
there was no difference in TLCO between subjects with and without hyperlipidemia [11–13].
Whether this also applies to patients with COPD is not known.
Based on these considerations the aim of our study was to analyze the relationship of hyper-
lipidemia to lung function, risk factors and comorbidities linked to hyperlipidemia in patients
with COPD. For this purpose we used data from the German COSYCONET (“COPD and SYs-
temic consequences-COmorbidities NETwork”) COPD cohort [14].
Material and methods
Study population
The analysis was based on the baseline data set (visit 1) of COSYCONET which is a multi-
center study focusing on the role of comorbidities in COPD [14]. Only patients of COPD
severity GOLD 1–4 [15] with complete data on forced expiratory volume in 1 second (FEV1),
intrathoracic gas volume (ITGV) and transfer coefficient for carbon monoxide (KCO), as well
as on age, gender, packyears of smoking, body-mass index (BMI) and the comorbidities hyper-
lipidemia, diabetes, and cardiovascular complex (see below) were included. This resulted in a
study population of n = 1746 out of 2741 patients recruited into COSYCONET [14]. The study
had been approved by the ethical committees of all study centers and all patients gave their
written informed consent.
Ethics approval and consent to participate
All assessments were approved by the central (Marburg (Ethikkommission FB Medizin Mar-
burg) and local (Bad Reichenhall (Ethikkommission bayerische Landesa¨rztekammer); Berlin
(Ethikkommission A¨rztekammer Berlin); Bochum (Ethikkommission Medizinische Fakulta¨t
der RUB); Borstel (Ethikkommission Universita¨t Lu¨beck); Coswig (Ethikkommission TU
Dresden); Donaustauf (Ethikkommission Universita¨tsklinikum Regensburg); Essen
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(Ethikkommission Medizinische Fakulta¨t Duisburg-Essen); Gießen (Ethikkommission Fach-
bereich Medizin); Greifswald (Ethikkommission Universita¨tsmedizin Greifswald);
Großhansdorf (Ethikkommission A¨rztekammer Schleswig-Holstein); Hamburg (Ethikkom-
mission A¨rztekammer Hamburg); MHH Hannover / Coppenbru¨gge (MHH Ethikkommis-
sion); Heidelberg Thorax/Uniklinik (Ethikkommission Universita¨t Heidelberg); Homburg
(Ethikkommission Saarbru¨cken); Immenhausen (Ethikkommission Landesa¨rztekammer Hes-
sen); Kiel (Ethikkommission Christian-Albrechts-Universita¨t zu Kiel); Leipzig (Ethikkommis-
sion Universita¨t Leipzig); Lo¨wenstein (Ethikkommission Landesa¨rztekammer Baden-
Wu¨rttemberg); Mainz (Ethikkommission Landesa¨rztekammer Rheinland-Pfalz); Mu¨nchen
LMU/Gauting (Ethikkommission Klinikum Universita¨t Mu¨nchen); Nu¨rnberg (Ethikkommis-
sion Friedrich-Alexander-Universita¨t Erlangen Nu¨rnberg); Rostock (Ethikkommission Uni-
versita¨t Rostock); Berchtesgadener Land (Ethikkommission Land Salzburg); Schmallenberg
(Ethikkommission A¨rztekammer Westfalen-Lippe); Solingen (Ethikkommission Universita¨t
Witten-Herdecke); Ulm (Ethikkommission Universita¨t Ulm); Wu¨rzburg(Ethikkommission
Universita¨t Wu¨rzburg)) ethical committees and written informed consent was obtained from
all patients. The study was conducted from September 2011 to December 2013 within the
COSYCONET framework (ClinicalTrials.gov, Identifier: NCT01245933) [14]. The approval
by the central ethics committee (University of Marburg) and the ethics committees of all other
studies centers (including University of Munich) comprises the statement that the study can
be conducted. This includes not only the collection of data but also the permission that the
analyses of the data outlined in the study protocol, as well as study questions developed on the
basis of accumulated experience and the collected data, can be performed. An additional
approval is only required if additional data are collected which were not part of the initial
approval or if patient-sensitive analyses are to be performed, such as genetic analyses of col-
lected samples without previous approval by the patient. In their written informed consent the
patients also agreed to the scientific evaluation of the collected data. The specific aim of the
present study, which comprised the analysis of three comorbidities and selected lung function
parameters, is therefore implicitly included in the approval by the ethics committees. Natu-
rally, in such a large cohort study including multiple parameters not all specific study questions
can be explicitly formulated from the beginning. The question of the present study was con-
tained in the bullet point “zu untersuchen, ob die Kombination funktioneller Indizes, system-
ischer Marker und klinischer Diagnosen es erlaubt, bislang unbekannte Pha¨notypen der
COPD zu definieren, die mo¨glicherweise einer unterschiedlichen Verlaufskontrolle und Ther-
apie bedu¨rfen”(translated: to study whether the combination of functional indices, systemic
markers and clinical diagnoses allows the definition of novel phenotypes of COPD which pos-
sibly require a different monitoring over time and therapy).
Methods
Protocol and methods have been described previously [14]. To facilitate the comparison with
previous cohorts we described the characteristics of our study population by a panel of param-
eters as well as the conventional categorizations (1–4 and ABCD) according to GOLD [15].
Moreover we used the conventional percentages of mean predicted values based on the fact
that the data on the deviations allowing for a lower limit of predicted was heterogeneous
among the predictions equations for the different parameters used. For the present analysis
comorbidities were assumed if either patients reported a doctor-based diagnosis, irrespective
of medication, or in the absence of a report, if disease-specific medication was identified; the
details of the procedure and the medication are given in a previous publication [16]. These def-
initions were named „extended definitions“. Since in cardiovascular diseases medication often
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is not specific for a single diagnosis but for two or three, we combined the three comorbidities
“arterial hypertension”, “cardiac failure” and “ischemic heart disease” into „cardiovascular
complex” [16]. The analysis was restricted to three comorbidities known to be closely linked to
each other based on clinical observations. Moreover in these comorbidities disease-specific
medication could be used to higher degree than in a variety of other comorbidities; the com-
plete list of comorbidities is given in our previous publication [14].
Lung function comprised spirometry, body plethysmography and carbon monoxide (CO)
diffusing capacity [14]. In addition to FEV1, ITGV and KCO, for the description of the popula-
tion the forced vital capacity (FVC), the ratio FEV1/FVC and transfer factor for CO (TLCO)
were chosen, each as percent of predicted. For the path analysis FEV1, ITGV and KCO were
taken as representatives of the domains obstruction, hyperinflation and gas exchange limita-
tion. Predicted values of FEV1, FEV1/FVC, FVC were taken from GLI [17], of ITGV from
EGKS [18], and of TLCO and KCO from van der Lee et al. [19]. As major risk factors we
included BMI, age, gender and packyears.
Statistical analysis
Data are presented as mean values and standard deviations (SD). Comparisons between the
two groups with and without hyperlipidemia were performed with the unpaired t-test irrespec-
tive of potential small deviations from normality (Kolmogorov-Smirnov-test) which com-
monly have no major impact on the test result. However, to be on the safe side and to check
whether these deviations affected the result we additionally employed the Mann-Whitney-U-
test and explicitly give the results for both types of tests. Categorical variables were compared
between groups using cross-tabulation and the chi-square-test statistics.
Next the association between variables was evaluated by standard multivariate linear and
binary logistic regression analyses comprising one dependent and multiple independent vari-
ables. These types of analyses are however limited to describe complex relationships in net-
works that can be represented by only two types of variables: dependent and independent. A
potential relationship between dependent variables as well as the possibility that the same vari-
able is both dependent and independent can be modeled by path analysis [20]. All analyses
were performed using SPSS Statistics 23 (IBM Corp., Armonk, NY, USA) and AMOS (IBM
Corp., Armonk, NY, USA). Statistical significance was assumed for p<0.05.
Results
Patients’ characteristics
Table 1 shows the patients’ characteristics (n = 1746) stratified for hyperlipidemia. In all
parameters except for FVC%pred, FEV1/FVC and TLC%pred there were significant differ-
ences between the two groups, in both parametric and non-parametric testing. For compari-
son the values for the total COSYCONET study population (GOLD 1–4, n = 2238) are given in
S1 Table; patients with and without hyperlipidemia again significantly differed in all parame-
ters except FEV1/FVC and TLC%pred. For selected lung function parameters the differences
between hyperlipidemia groups remained significant after adjustment for risk factors and are
illustrated in Fig 1.
Fig 2 shows the prevalence of hyperlipidemia in patients with and without diabetes or car-
diovascular complex. Both were significantly (p<0.001 each) associated with hyperlipidemia.
Overall these results showed that (a) our observations were in accordance with other cohorts
and that (b) it would be reasonable to implement the relationships between comorbidities, and
not only their relation to risk factors or lung function, into a statistical model.
Relationship of hyperlipidemia to lung function: Results of the COSYCONET COPD cohort
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Results of path analysis models
We first performed standard multivariate linear and logistic regression analyses (see Tables
A-C in S1 Text). Based on their results we constructed a sequence of path analysis models
which allowed the description of more complex relationships, particularly between dependent
variables. To build a final model in a systematic way, two preliminary models were evaluated
(see S1 and S2 Figs). In this model the variables were arranged into three „layers“: on top the
risk factors (BMI, age, gender, packyears), as intermediates the comorbidities (diabetes, hyper-
lipidemia, cardiovascular complex), and at the bottom lung function (ITGV%pred, FEV1%
pred, KCO%pred).
Final model comprising risk factors, comorbidities and lung function. The final model
(Fig 3) was constructed as a composite of the two preliminary models (S1 and S2 Figs). Based
on the regression results (Table C in S1 Text) we additionally introduced a number of relation-
ships between comorbidities and lung function but kept only those which turned out to be sta-
tistically significant, i.e. that between hyperlipidemia and ITGV and that between
cardiovascular complex and FEV1. Parameter values and significance levels of the final model
Table 1. Baseline characteristics of the subgroups with and without hyperlipidemia.
Parameter All patients Hyperlipidemia
(extended def.)
Non-Hyperlipidemia p-values
N (%) 1746 749 (42.9%) 997 (57.1%) -
Gender (m/f) 1092/654 498/251 594/403 p = 0.003*
Age (y) 64.6 (±8.4) 65.8 (±7.8) 63.8 (±8.8) p<0.001*
BMI (kg/m2) 26.8 (±5.3) 27.6 (±5.2) 26.2 (±5.2) p<0.001*
Waist circ. (cm) 99.6 (±15.6) 102.1 (±15.3) 97.7 (±15.5) p<0.001*
Packyears 49.2 (±35.8) 52.4 (±37.8) 46.7 (±34.0) p = 0.001*
Hb (mg/dl) 14.71 (±1.34) 14.59 (±1.42) 14.79 (±1.29) p = 0.003*
Creatinine (mg/dl) 0.90 (±0.24) 0.93 (±0.26) 0.87 (±0.22) p<0.001*
Triglycerides (md/dl) 141.5 (±106.6) 156.9 (±111.1) 129.9 (±101.7) p<0.001*
Total cholesterol (mg/dl) 214.2 (±43.4) 209.6 (±48.2) 217.8 (±39.1) p<0.001*
LDL (mg/dl) 126.8 (±38.0) 123.1 (±41.5) 129.5 (±34.9) p0.001*
HDL (mg/dl) 64.1 (±20.9) 61.9 (±20.8) 65.8 (±20.9) p<0.001*
FEV1%pred 56.9 (±19.1) 58.6 (±18.8) 55.6 (±19.3) p = 0.001*
FEV1/FVC 54.7 (±13.8) 55.0 (±13.6) 54.6 (±19.3) p = 0.451
FVC%pred 78.3 (±19.1) 77.6 (±19.3) 78.9 (±19.0) p = 0.166
TLC%pred 110.9 (±29.8) 109.8 (±29.0) 111.7 (±30.3) p = 0.188
RV%pred 153.9 (±45.3) 148.0 (±42.5) 158.4 (±46.9) p<0.001*
ITGV%pred 149.4 (±35.0) 144.1 (±33.9) 153.3 (±35.2) p<0.001*
VA (liter) 4.7 (±1.6) 4.8 (±1.6) 4.7 (±1.7) p = 0.316
TLCO%pred 50.6 (±19.7) 52.1 (±19.1) 49.5 (± 20.1) p = 0.006*
KCO%pred 64.0 (±22.4) 66.5 (±22.1) 62.1 (±22.6) p<0.001*
GOLD 1/2/3/4 232/934/24/584 106/367/242/34 126/438/363/70 p = 0.022*
GOLD A/B/C/D 199/934/24/582 82/396/6/264 117/538/18/318 p = 0.123
The table shows mean values and standard deviations or absolute numbers. Lung function parameters are given in terms of %predicted, except for alveolar
volume, VA, which is given in liters. Column 4 shows the results of comparisons between the hyperlipidemia group (extended definition) and the
complementary group of non-hyperlipidemia patients. The comparisons between groups were performed by unpaired t-tests, either for equal or unequal
variances depending on the data, or by chi-square-tests in the case of categorical variables. The results of t-tests were checked by the Mann-Whitney-U-
test to accommodate for deviations from normality; the results of both approaches were qualitatively equivalent. Significant (p<0.05) differences are marked
with (*).
https://doi.org/10.1371/journal.pone.0177501.t001
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are shown in Table 2. The model fitted the data with a chi-squared of 18.79 at 21 degrees of
freedom (p = 0.60; see above) and was also well-fitting according to the bootstrap procedure
using 2000 samples and the Bollen-Stine method (chi-squared 21.54, p = 0.61).
Discussion
In the present analysis we investigated the relationship between risk factors, comorbidities and
lung function in a large cohort of patients with COPD. The comorbidities comprised a combi-
nation of cardiovascular diseases and diabetes, as well as hyperlipidemia [2, 3]. Its prevalence
was 42.9% according to self-reported doctors’ diagnoses and disease-specific medication.
Based on linear and logistic regression results an integrative path analysis model was built that
illustrated the place of hyperlipidemia in the network of risk factors, other comorbidities and
lung function. Hyperlipidemia was dependent on age, BMI, diabetes and cardiovascular dis-
eases. Even after adjustment for confounders it was associated with lower ITGV and higher
FEV1, beyond the direct and indirect links from BMI and age. This apparently protective effect
might be related to the phenotype of COPD as well as beneficial effects of medication targeted
at hyperlipidemia. In our analyses we required complete data sets and therefore had to exclude
a number of patients. However comparison of the descriptive Table 1 and S1 Table does not
indicate a selection bias introduced by this.
To understand the relationship between the different entities we first performed multivari-
ate regression analyses comprising the risk factors age, packyears, BMI and gender, the three
Fig 1. Adjusted effects of hyperlipidemia on lung function. The figure shows the differences between patients with and without
hyperlipidemia for three selected lung function parameters representing airway obstruction, lung volume and alveolar gas exchange. These
differences are based on multivariate regression analyses adjusting for age, gender, BMI and packyears, as major confounders some of
which were different between groups. The circles represent mean values and the vertical bars 95% confidence intervals, showing that even
after adjustment there were significant (p<0.05) differences in FEV1 and ITGV.
https://doi.org/10.1371/journal.pone.0177501.g001
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comorbidities and a variety of lung function parameters. For path analysis we focused on sin-
gle representatives of obstruction (FEV1%pred), hyperinflation (ITGV%pred) and gas
exchange (KCO%pred). Among the comorbidities a combined entity “cardiovascular com-
plex” was defined comprising arterial hypertension, cardiac failure and ischemic heart disease.
The comorbidities depended on age, BMI and partially on gender (Table A in S1 Text), while
lung function depended on BMI, age and gender, diffusing capacity additionally on packyears
(Table B in S1 Text). Diabetes was related to lung volume and diffusing capacity, cardiovascu-
lar complex to obstruction and lung volume, and hyperlipidemia to all three lung function
parameters (Table C in S1 Text).
Thus hyperlipidemia was linked to risk factors as well as lung function. It was associated
with relatively better FEV1, while diabetes and cardiovascular complex were linked to relatively
lower FEV1. The observation regarding hyperlipidemia and FEV1 appeared to be in contrast to
findings in obese lung-healthy subjects [21] but in COPD the situation might be more compli-
cated due to the presence of risk factors influencing both lung function and comorbidities. To
analyse the complex network of direct and indirect effects we used the statistical procedure of
path analysis.
Path analysis is a well-founded statistical procedure widely used in empirical social sciences
and econometrics [20]; it has also been used in medical studies to evaluate complex associa-
tions [22, 23]. Essentially it is an extension of multivariate regression allowing for hierarchical
relationships as well as bypassing these hierarchies and thus the quantification of both direct
and indirect effects all of which can be visualized graphically; indirect effects are those medi-
ated through other variables (see S1 Text). The possibility to introduce relationships between
Fig 2. Prevalence of hyperlipidemia versus diabetes and cardiovascular complex. Diabetes and cardiovascular complex were
associated with hyperlipidemia. Significant differences (p<0.001) were marked with (*).
https://doi.org/10.1371/journal.pone.0177501.g002
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dependent variables accounts for known or suspected links between them, in addition to the
“downward” relationships quantified by conventional regression. We first analysed two pre-
liminary models which comprised risk factors and either comorbidities (S1 Fig) or lung func-
tion (S2 Fig). These models showed that (a) the assumed additional relationships were
statistically valid and (b) that no further significant relationships could be demonstrated. Irre-
spective of this it has to be kept in mind that path analysis is a hypothesis-driven procedure
and that in general there may be statistically equivalent models. The choice between them has
to be based on physiological and clinical knowledge. On the other hand the procedure is capa-
ble of excluding models that do not adequately describe the data [20].
The final model (Fig 3) was constructed as overlay of the preliminary models. Additionally
we introduced relationships between comorbidities and lung function taking into account the
results of the respective regression analysis (Table C in S1 Text). Only the relationships
between hyperlipidemia, FEV1%pred and ITGV%pred remained as significant and were kept
in the model. It seems remarkable that these direct links from hyperlipidemia were still rele-
vant when multiple confounders were taken into account but this was in accordance with
comparisons adjusting for risk factors (Fig 1). The link from hyperlipidemia to ITGV acted in
parallel to the direct effect of BMI and had the same sign, i.e. hyperlipidemia was associated
with less hyperinflation. This reduction of ITGV might reflect an additional mechanical influ-
ence in obese subjects that is not adequately described by BMI, such as a different distribution
of body mass. To check this possibility we repeated the analysis with waist circumference as
predictor instead of BMI. The overall model fit was still acceptable, and the links between
Fig 3. Results of path analysis. Final path analysis model comprising three layers: risk factors, comorbidities and lung function
parameters. The structure only contains relationships which turned out to be statistically significant (p<0.05 each). Error terms of dependent
variables have been omitted for the sake of clarity. Correlations between the independent variables are indicated by arched arrows.
https://doi.org/10.1371/journal.pone.0177501.g003
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hyperlipidemia and ITGV%pred as well as FEV1%pred remained significant. Therefore we
considered BMI as adequate in the model.
Among the comorbidities of COPD known to be linked to hyperlipidemia, diabetes and
cardiovascular diseases are the most prevalent ones [3]. We therefore restricted the analysis to
these two conditions. One of the advantages was that these comorbidities could also be evalu-
ated via analysis of disease-specific medication in addition to patients’ report [16]. This how-
ever required that the three diseases arterial hypertension, cardiac failure and ischemic heart
disease were combined into to a single entity termed “cardiovascular complex”, since many
medications are specific for a combination of these diseases but not for a single one.
Table 2. Results of the final path analysis model.
Regression Estimate S.E. C.R. Standardized
Estimate
p-value
Diabetes  BMI .059 .007 8.311 .196 p<0.001
Diabetes  Gender -.102 .014 -7.069 -.147 p<0.001
Diabetes  Age .016 .007 2.361 .053 p = 0.018
Cardiovascular complex  BMI .072 .010 7.350 .168 p<0.001
Cardiovascular complex  Diabetes .186 .026 7.186 .130 p<0.001
Cardiovascular complex  Gender -.100 .023 -4.335 -.101 p<0.001
Cardiovascular complex  Age .081 .010 8.052 .184 p<0.001
Dyslipidemia  Diabetes .224 .034 6.574 .152 p<0.001
Dyslipidemia  Cardiovascular complex .169 .024 6.899 .163 p<0.001
Dyslipidemia  BMI .036 .011 3.375 .080 p<0.001
Dyslipidemia  Age .023 .011 2.191 .051 p = 0.028
ITGV  BMI -.314 .022 -14.415 -.313 p<0.001
ITGV  Age -.105 .022 -4.663 -.102 p<0.001
ITGV  Dyslipidemia -.121 .051 -2.363 -.054 p = 0.018
FEV1  ITGV -.521 .019 -28.093 -.533 p<0.001
FEV1  Cardiovascular complex -.242 .046 -5.211 -.106 p<0.001
FEV1  Dyslipidemia .121 .046 2.635 .055 p = 0.008
KCO  ITGV -.193 .027 -7.200 -.193 p<0.001
KCO  FEV1 .234 .025 9.206 .228 p<0.001
KCO  Packyears -.110 .021 -5.304 -.109 p<0.001
KCO  BMI .233 .021 10.839 .232 p<0.001
KCO  Age .074 .021 3.523 .073 p<0.001
Covariances
BMI $ Packyears .143 .029 4.969 .116 p<0.001
Packyears $ Age .099 .029 3.465 .082 p<0.001
The upper panel refers to the directed arrows (linear regression terms) depicted in Fig 2. The left part of this panel lists the arrows shown in this figure, the
right part shows the results of the corresponding statistical tests. The first column of the right part shows the non-standardized estimate of the respective
regression coefficient, the second column the standard error of this coefficient (S.E.), the third column the ratio of these two (critical ratio. C.R.) which is
used for significance testing. The forth column shows the standardized estimates of the regression coeffients shown in the first column. The last column
shows the significance level based on the asymptotically distribution-free estimation procedure of AMOS. All coefficients were also significant when using
the standard maximum likelihood estimation procedure despite the deviations from normal distribution for nearly all variables. The standardized estimates
are given since they allow for the evaluation of direct and indirect effects: direct effects from one variable onto the other are given by the respective
standardized regression coefficient, whereas indirect effects mediated through a third variable are given by the multiplication of the two standardized
regression coefficients between the respective variables. The lower panel shows the covariances (bidirectional arrows) between the risk factors that were
part of the model, as well as the respective standard errors, critical ratios and significance levels. The standardized covariances represent the respective
correlation coefficients.
https://doi.org/10.1371/journal.pone.0177501.t002
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Comparing to reported diagnoses, the prevalence for diabetes increased through the consider-
ation of specific medication from 12.6 to 12.9%, for the cardiovascular complex from 60.0 to
64.7%, and for hyperlipidemia from 37.9 to 42.9%. Probably the estimates including the infor-
mation from medication are more reliable than those based on reports only. When using the
latter, the overall fit of the model was reduced but still significant; importantly, the links
between hyperlipidemia, ITGV and FEV1 remained significant. This indicates that the
extended definitions of comorbidities (a) improved the results and (b) did not introduce arte-
facts compared to the reported diagnoses.
As risk factors we considered age and gender, as well as packyears and BMI, which were
either independent of the individual behaviour, or linked to lifestyle. All of them are known to
be correlated with comorbidities and lung function, and indeed their association with cardio-
vascular diseases was consistent with previous findings [24]. The same was true for the associa-
tions between BMI and hyperlipidemia [25] or diabetes [26], or between diabetes and
cardiovascular diseases [27], or between diabetes, cardiovascular diseases and hyperlipidemia
[3]. This suggests that the COSYCONET data set did not deviate from other data sets in a sig-
nificant way, irrespective of the diagnosis of COPD. In particular this refers to the link between
hyperlipidemia and lung volume which turned to be robust in various statistical analyses. The
comorbidities were part of the final model in order to include as much as possible of the
known confounders and thereby to identify both direct and indirect associations of hyperlipid-
emia via their standardized effects (see legend to Table 2). For example, hyperlipidemia was
directly linked to age (Table 2; standardized effect 0.045; see also Fig 2) but also indirectly
linked to age via diabetes as well as cardiovascular complex which corresponded to an overall
indirect effect of 0.039. Thus direct and indirect effects were of similar magnitude. This type of
quantification is possible only with path analysis through multiplication of the respective stan-
dardized coefficients.
The findings regarding lung volume fit into the hypothesis that COPD patients with higher
BMI and/or hyperlipidemia more often show a COPD phenotype of obstructive bronchitis
rather than emphysema. We did not have such phenotype information, e.g. based on CT
scans, and the pattern of lung function alterations did not uniquely allow the differentiation.
The observed inverse association between ITGV and FEV1 (Table 2) is known but not specific
for emphysema [28], and the relationship between BMI and relatively higher FEV1 is consis-
tent with less emphysema in patients of higher weight [29]. The direct link from packyears to
lower KCO possibly reflected the degree of emphysema, thereby abolishing a potential effect of
dyslipidemia (Fig 1), and the association of higher ITGV with lower KCO (Table 2) their
known volume-based relationship. As TLCO is directly proportional to lung volume we pre-
ferred the use of KCO, although KCO also does not fully normalize for volume. Moreover the
model fit with KCO was superior to that with TLCO.
The positive association between hyperlipidemia and FEV1 (Table 2) might be surprising at
the first view but is not necessarily in conflict with findings that lung-healthy subjects with
hyperlipidemia/metabolic syndrome showed a reduced FEV1, since we studied patients with
COPD, i.e. inflammatory lung disease. Remarkably, patients with COPD and hyperlipidemia
appear to have a better outcome in pneumonia-related exacerbations and mortality [4, 5]. It
may also be noteworthy that several studies described an anti-inflammatory action of simva-
statin [30], an improved FEV1 in patients undergoing this therapy [31] a protective effect
against the development of emphysema [32], in accordance with the, on average, better FEV1
and KCO in our patients (Table 1). Whether hyperlipidemia-related inflammation favours a
specific phenotype of COPD is not known; for diabetes CT data indicate a predominant non-
emphysematous type of COPD [33]. Although the differences of lung function parameters
between both groups were small, they might become relevant in case of exacerbations.
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The diagnosis of hyperlipidemia used in our analyses was based on patients’ reports and
medication, while the effectiveness of their lipid-lowering therapy was illustrated by the com-
parison of patients with and without the diagnosis of hyperlipidemia (Table 1 and S1 Table).
This was the reason why we could not use lipids for the definition of hyperlipidemia and did
not include them into the path analysis. Overall 23.8% of patients received hyperlipidemia-spe-
cific medication [20], the others either non-specific medication and/or dietetics recommenda-
tions. When ITGV%pred was evaluated with BMI, age, gender and packyears as confounders,
it turned out to be still significantly reduced for both patients with specific and non-specific
medication. These observations show that the major difference in patients with the diagnosis
of hyperlipidemia compared to those without was the presence of medication and not an
increase in lipid levels. It is therefore tempting to attribute our findings to effects of
medication.
One of the limitations of our study was that we could characterize the population by con-
ventional lipid parameters but hardly include these in the analyses since they apparently were
affected by therapy. A similar situation occurred for cardiovascular diseases. We therefore pre-
ferred not to use biomarkers in this analysis. The identification of comorbidities was based on
patients’ reports only but we tried to alleviate this limitation as much as possible by using the
extended, medication-based definitions. Moreover we did not have detailed information on
the phenotype of COPD, e.g. from CT scans. The strength of the study was the large data set,
the possibility to evaluate three comorbidities by analysis of medication, and the use of path
analysis beyond conventional multivariate regression. The statistical evaluation of the model
depended on assumptions on data distribution which were not met with our data, but we used
asymptotically distribution-free estimation in a sufficiently large data set [24] and the fit was
confirmed by other estimation procedures. Furthermore we incorporated into the final model
as much as possible of the already known associations thereby aiming to describe the role of
hyperlipidemia in COPD in the whole context of other alterations.
Conclusion
Using the large baseline data set of the German COPD cohort COSYCONET we evaluated the
relationship between risk factors, hyperlipidemia, diabetes, a combination of cardiovascular
diseases and lung function. Hyperlipidemia was associated with lower ITGV and higher FEV1
even if its direct and indirect links to diabetes and cardiovascular disease, or age, gender and
BMI were taken into account, and there was no hint towards an impairment of lung function
associated with hyperlipidemia, similar to that previously found for diabetes. The result was
statistically robust within a path analysis model and multivariate regression analyses suggest-
ing that COPD patients with hyperlipidemia showed less lung hyperinflation and airway
obstruction than those without hyperlipidemia. Whether this reflected differences in COPD
phenotype or was related to other factors including medication remains to be clarified.
Supporting information
S1 Fig. Premliminary path analysis model 1. Preliminary path analysis model comprising
two layers, on the top risk factors and as intermediate layer comorbidities. All of the relation-
ships shown were statistically significant (p<0.05 each). Error terms of dependent variables
have been omitted for the sake of clarity. There were no significant correlations between the
independent variables.
(TIF)
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S2 Fig. Preliminary path analysis model 2. Preliminary path analysis model comprising two
layers, on the top risk factors and as bottom layer lung function parameters. All of the relation-
ships shown were statistically significant (p<0.05 each). Error terms of dependent variables
have been omitted for the sake of clarity. There were no significant correlations between the
independent variables.
(TIF)
S1 Table. Baseline characteristics of the subgroups with and without hyperlipidemia
(n = 2238, total cohort GOLD 1–4). The table shows mean values and standard deviations
or absolute numbers. Lung function parameters are given in terms of %predicted, except for
alveolar volume, VA, which is given in liters. Column 4 shows the results of comparisons
between the hyperlipidemia group (extended definition) and the complementary group of
non-hyperlipidemia patients. The comparisons between groups were performed by unpaired
t-tests, either for equal or unequal variances depending on the data, or by chi-square-tests in
the case of categorical variables. The results of t-tests were checked by the Mann-Whitney-U-
test to accommodate for deviations from normality; the results of both approaches were quali-
tatively equivalent. Significant (p<0.05) differences are marked with ().
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